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Abstract
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited
myocardial disease characterized by fibro-fatty replacement of the right ventricular
myocardium, and associated with paroxysmal ventricular arrhythmias and sudden car-
diac death (SCD). It is currently the second most common cause of SCD after hyper-
trophic cardiomyopathy in young people <35 years of age, causing up to 20% of
deaths in this patient population. This condition has a male preponderance and is more
commonly found in individuals of Italian and Greek descent. To date, there is no single
diagnostic test for ARVC/D and the diagnosis is made based on clinical, electrocardio-
graphic, and radiological findings according to the Revised 2010 Task Force Criteria. In
this review, we will discuss the mainstay treatment which includes pharmacotherapy,
implantable cardioverter-defibrillator insertion for abortion of sudden cardiac death,
and in the advanced stages of the disease cardiac transplantation.
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1 | INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/
D) is an uncommon inherited cardiac disease characterized by pro-
gressive right ventricular (RV) dysfunction due to fibro-fatty replace-
ment of the myocardium and associated with high risk of ventricular
arrhythmias and sudden cardiac death (SCD).1,2 ARVC/D has a pre-
dominantly autosomal dominant inheritance, although recessive
forms associated with a cutaneous phenotype, such as Naxos dis-
ease and Carvajal syndrome, are also observed.3,4 Despite RV abnor-
malities being the predominant finding, it has been recently
appreciated that patients with ARVC/D may also have some degree
of left ventricular (LV) involvement5 and indeed severe LV impair-
ment can sometimes be the initial manifestation of the disorder.6 An
LV-predominant form of ARVC/D has recently been described.7
Independently of which ventricle is initially or predominantly
affected, during the later stages, advanced disease can result in
biventricular heart failure, which may closely resemble dilated car-
diomyopathy (DCM). LV dysfunction is observed more frequently
with greater RV dysfunction, worse functional class, and leads to an
increased tendency to cardiovascular adverse events relating to
heart failure.8 The same study showed no clear relationship between
LV involvement and an increased rate of arrhythmic events.8 Clinical
manifestations vary with the age of the patient and stage of dis-
ease.9 In this article, we will review the pathophysiology or ARVC/D,
the main diagnostic modalities used clinically aiding the diagnosis
and patient management.
2 | PATHOPHYSIOLOGY OF ARVC/D
The pathophysiological mechanisms in ARVC/D involve desmosomal
abnormalities that can arise from mutations in cell adhesion proteins
or intracellular signaling components.10 A number of genes have
been implicated in the pathogenesis of ARVC/D,11 as illustrated in
Table 1. Particularly, reduced cardiac desmoglein-2 and desmocollin-
2 levels appear to be specifically associated with ARVC/D, indepen-
dent of the gene mutations found.12 The desmosome normally main-
tains cell-to-cell adhesion and confers mechanical strength to tissues
(Figures 1 and 2). In the extracellular space, desmosomal cadherins
(desmocollin and desmoglein) bind strongly to each other. Cadherins
span the plasma membrane and attach to linker proteins (plakoglo-
bin, desmoplakin, and plakophilin-2) in the intracellular space.1 Plako-
globin and desmoplakin are intracellular proteins anchoring
desmosomes to desmin intermediate filaments. Moreover, plakoglo-
bin contributes to interlinking adherens junctions with the actin
cytoskeleton and participates in cellular signaling to the nucleus and
desmosome organization.13,14 Defects in linking sites of these pro-
teins can interrupt cell adhesion, especially under conditions of
increased mechanical stress or stretch, leading to cell death, progres-
sive loss of myocardium, and fibro-fatty replacement.15 As such, sur-
viving myocardial fibers within the fibro-fatty tissue from zones of
slow conduction provide a medium for re-entry ventricular arrhyth-
mias.16-19 The degeneration-inflammation model posits that the
resulting cellular damage is found in tissues under high mechanical
stress.1 Indeed, this notion is in keeping with the observations that
exercise increases age-related penetrance and risk of arrhythmias in
ARVC/D-associated mutation carriers.20 The potential role of cal-
cium-sensitive pathways in the pro-arrhythmia mechanism of ARVC/
D has been proposed.21 In a recent meta-analysis, however, the
presence of desmosomal gene mutations was not associated with
global or regional structural and functional alterations, epsilon wave,
or VT of left bundle branch morphology.22
3 | CLINICAL PRESENTATION
Classically, ARVC/D usually presents between the second and fourth
decades of life with syncope, symptomatic arrhythmias, or SCD. An
example of monomorphic VT in a patient with ARVC/D is shown in
Figure 3 (reproduced from23 with permission). Chest pain can be the
presenting finding of the disorder.24 One-third of the patients
become symptomatic before the 30th year of life. ARVC/D can lead
to deleterious consequences, such as ventricular arrhythmias, pump
failure, and death. Competitive sports have been associated with a
twofold increased risk of ventricular arrhythmias and mortality, and
earlier presentation of symptoms comparing with inactive patients
and patients who participated in recreational sport.25 Another inter-
esting finding is the relation between meteorological factors and
outcomes in patients with ARVC/D. Particularly, higher temperature
and larger variation in humidity within 3 days of events were inde-
pendently associated with the development of ventricular arrhythmic
TABLE 1 Updated gene list responsible for ARVC/D pathology
Subtype Gene Location Reference
ARVC1 TGFB3 14q24.3 89
ARVC2 RYR2 1q43 90
ARVC3 Unknown 14q12-q22 91
ARVC4 TTN 2q32.1-q32.3 92
ARVC5 TMEM43 3p25.1 93
ARVC6 Unknown 10p14-p12 94
ARVC7 DES 2q35 95
ARVC8 (Carvajal) DSP 6p24.3 96
ARVC9 PKP2 12p11 97
ARVC10 DSG2 18q12.1 98
ARVC11 DSC2 18q12.1 99
ARVC12 (Naxos) JUP 17q21.2 15
Others PLN 6q22.1 100
LMNA 1q22 101
SCN5A 3p21 102
CTNNA3 10q22.2 103
CDH2 – 104
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and sudden mortality events.26 Intracardiac thrombosis may occur in
certain patients with ARVC/D.27 Atrial arrhythmias are also common
in ARVC/D and present at a younger age than in the general popula-
tion.28 Atrial arrhythmias are associated with male gender, increasing
age, and left atrial dilation and clinically important, and they are
associated with inappropriate implantable cardioverter-defibrillator
shocks29 and increased risk of both heart failure and death.28 In
addition to tachy-arrhythmias, brady-arrhythmias are also observed
in this condition.30
4 | DIAGNOSING ARVC/D: THE
CHALLENGES
There is no single diagnostic test for ARVC/D. The diagnosis is made
based on major and minor clinical, electrical, and imaging criteria that
have been devised by expert consensus of the Task Force Criteria
(TFC) originally proposed in 1994 and further revised in 2010
(Table 2).31 In the original 1994 TFC, the clinical diagnosis was based
strongly on symptomatic index cases and SCD victims—those with
overt and severe phenotypes. Consequently, the 1994 criteria were
highly specific, but they lacked sensitivity for early and familial dis-
ease.32-35 A systematic review and meta-analysis of five retrospec-
tive studies compared the diagnostic concordance between the
1994 and 2010 criteria.36 8.6% and 3.6% satisfied the 1994 and
2010 major criteria, whereas 29.2% and 1.9% satisfied their minor
criteria. Therefore, the 2010 revised TFC have resulted in a signifi-
cant reduction in the number of patients that satisfy the cardiovas-
cular magnetic resonance criteria and in a statistically significant
increase in the number of patients diagnosed with definite ARVC/D
compared to the 1994 criteria.36 Since then, modifications of the
original criteria have been proposed to facilitate clinical diagnosis in
F IGURE 1 Desmosomes (arrows)
connect cytoskeletons of adjacent cells
(myofibrils, double arrows) and contain
centrally dense lamellae composed of
polypeptides, plakoglobin, and other
proteins. Clusters of mitochondria
(asterisks) can be seen
F IGURE 2 The desmosomes (ellipse)
show dense cell borders and glycoproteins
in the intercellular space. Plakoglobin is a
plaque protein of intercellular junctions
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first-degree relatives, who often have an incomplete disease pheno-
type.37 According to these recommendations, familial ARVC/D is
said to occur when the following conditions are met: (i) T-wave
inversion in the right precordial leads in individuals older than
14 years of age; (ii) late potentials by signal-averaged ECG (SAECG);
and (iii) ventricular tachycardia with left bundle branch block mor-
phology on the ECG or exercise testing or >200 premature ventricu-
lar contractions in 24 hours.
4.1 | Electrocardiography
In the ECG, epsilon waves, which are late potentials occurring
between the end of the QRS complex and the onset of the T-wave,
and T-wave inversion in the right precordial leads of V1 to V3 may
be observed. Epsilon waves are specific for ARVC/D although it is
only observed in 30% of patients and are best seen in the right pre-
cordial leads V1-V3 (Figure 4). Particularly, epsilon waves in lead
aVR in patients with arrhythmogenic right ventricular cardiomyopa-
thy are rare electrocardiographic findings with a specificity of
100%.38 The detection of epsilon waves on 12-lead ECG has been
associated with higher episodes of sustained VT, but reassuringly,
this did not lead to increased SCD incidence.39 A case of a child with
extensive involvement of both right and left ventricular walls and
epsilon waves in all precordial leads has been reported.40 However,
interobserver variability in the assessment of epsilon waves is high.41
As a result, the assessment of the epsilon waves must be performed
cautiously particularly in patients with who would not otherwise
meet diagnostic criteria. The sensitivity of epsilon waves on the ECG
is low between 25% and 38%, and therefore, a normal ECG does
not exclude the diagnosis of ARVC/D.42,43 The use of Fontaine bipo-
lar precordial lead electrocardiography (F-ECG) increased the sensi-
tivity to 50%.43 Electrical abnormalities in ARVC/D are important as
these changes precede structural changes.44
A more specialized electrocardiographic technique, known as sig-
nal-averaged electrocardiography (SAECG), can also be utilized. It
aims to filter interference, unmask any microvariations, and display
late potentials (if any) within the QRS complex by averaging the mul-
tiple electrical signals generated by the heart.45 Late potentials are
thought to represent electrical depolarization abnormalities and are
defined within the minor depolarization criteria in the 2010 TFC
(Table 2). The criteria include the following:
1. Filtered QRS duration ≥114 ms
2. Duration of terminal QRS <40 lV: ≥38 ms
F IGURE 3 An electrocardiogram (ECG) showing monomorphic ventricular tachycardia (VT) with a left bundle branch block pattern with
superior axis from a patient with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). Figure reproduced from ref. 23 with
permission
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3. Root-mean-square voltage of terminal 40 ms: ≤20 lV
As long as any of the above is satisfied, the minor criterion in
the 2010 TFC is fulfilled. Even though SAECG can be useful, it must
be noted that an abnormal SAECG is not specific to ARVC as it can
also be seen in other conditions such as myocarditis and scarring in
ischemic heart disease.
4.2 | Imaging: echocardiography and cardiac
magnetic resonance (CMR)
Noninvasive imaging modalities such as echocardiography and CMR
can be used to identify structural and functional abnormalities
described in the revised TFC. It is also possible to investigate these
invasively using RV angiography. Echocardiographic features of
TABLE 2 International Task Force Criteria modified in 2010 (reproduced from 31 with permission)
Domain Major criteria Minor criteria
Family history • ARVD confirmed in a first-degree relative
• ARVD confirmed at surgery or autopsy
in a first-degree relative
• Pathogenetic mutation in a gene
associated with ARVD
• History of ARVD in a first-degree relative in whom it was not possible
to determine whether the current Task Force Criteria is met
• Premature death at <35 years of age due to suspected ARVD
• ARVD confirmed pathologically or by current Task Force criteria in a
second-degree relative
ECG abnormalities • Epsilon wave (reproducible low-amplitude
signals between end of QRS complex and
beginning of T-wave in leads V1 to V3
• Inverted T-waves in leads V1 to V3 in
individuals >14 years
of age in the absence of RBBB
and QRS ≥120 ms)
• Late potentials by signal-averaged ECG in ≥1 of 3 parameters in an
absence of QRS ≥110 ms
• Filtered QRS duration ≥114 ms
• Duration of terminal QRS <40 lV and ≥38 ms
• Root-mean-square voltage of terminal QRS <40 ms and ≤20 lV
• Terminal activation duration of QRS ≥55 ms measured between the nadir
of the S wave and the end of the QRS complex, including R’, in V1, V2,
or V3, without RBBB
• T-wave inversion in V1 and V2 in individuals >14 years of age in an
absence of RBBB, or in V4 to V6
• T-wave inversion in leads V1 to V4 in individuals >14 years of age in the
presence of complete RBBB
Arrhythmias • Nonsustained or sustained VT
with a LBBB morphology
with superior axis (negative
or indeterminate QRS in
leads II, III, and aVF and positive in aVL)
• Nonsustained or sustained VT of RVOT configuration, LBBB morphology
with inferior axis (positive QRS in leads II, III, and aVF and negative in
aVL) or of unknown axis
• 500 ventricular extrasystoles within 24 h on Holter monitoring
Tissue characteristics • Fibro-fatty replacement of the myocardium
on endomyocardial biopsy
• Residual myocytes <60% by morphometric analysis (or <50% if estimated)
with fibrous replacement of the RV free wall myocardium in >1 sample,
with or without fatty replacement of tissue on endomyocardial biopsy
• Residual myocytes 60%-75% morphometric analysis (or 50%-65% if
estimated) with fibrous replacement of the RV free wall myocardium
in >1 sample, with or without fatty replacement of tissue on
endomyocardial biopsy
Global or regional functional or structural abnormalities
Echocardiography • Regional RV akinesia, dyskinesia, or aneurysm
and one of the following at end diastole:
o PLAX RVOT ≥32 mm (corrected for body
size [PLAX/BSA] ≥19 mm/m
2)
o PLAX RVOT ≥36 mm (corrected for body
size [PLAX/BSA] ≥21 mm/m
2)
o Fractional area change ≤33%
• Regional RV akinesia, dyskinesia, and one of the following at end diastole:
o PLAX RVOT ≥32 and <36 mm (corrected for body size [PLAX/BSA]
>18 and <21 mm/m
2)
o PLAX RVOT ≥29 and <32 mm (corrected for body size [PLAX/BSA]
>16 and <19 mm/m
2)
o Fractional area change >33% and ≤40%
MRI • Regional RV akinesia or dyskinesia or
dyssynchronous RV contraction and
one of the following:
o Ratio of RV end-diastolic volume to
BSA ≥110 mL/m
2 (male)
or ≥100 mL/m2 (female)
o RV ejection fraction ≤40%
• Regional RV akinesia or dyskinesia and one of the following:
o Ratio of RV end-diastolic volume to BSA ≥100 mL/m
2 and
<110 mL/m2 (male) or ≥90 mL/m2 and <100 mL/m2 (female)
o RV ejection fraction >40% and ≤45%
RV angiography • Regional RV akinesia, dyskinesia, or aneurysm • Regional RV akinesia, dyskinesia, or aneurysm
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ARVC/D include global ventricular dilatation (Figure 5), reduced RV
ejection fraction with normal LV, or mild segmental dilatation of the
RV or regional RV hypokinesis.31 CMR similarly demonstrates these
abnormalities but at a higher resolution (Figure 6). There are several
advantages of CMR over echocardiography. Firstly, it provides gold
standard values for both LV and RV volumes. Secondly, it provides
clear delineation of RV anatomy for micro-aneurysms and trabecula-
tions. Thirdly, it can clearly visualize RV hypokinesis and akinesis.46
All of these features are part of the 2010 criteria, making CMR an
excellent modality for diagnosis. Moreover, CMR can help to identify
conditions that can mimic ARVC/D.46 For example, Khaji et al47 pre-
sented a patient with mega-epsilon wave, right ventricular dilatation,
and inducible VT that was initially diagnosed as ARVC/D by the Task
Force Criteria. Further examination with endomyocardial biopsy
revealed the diagnosis of sarcoidosis.47 A study which compared
clinical and electrophysiological parameters between patients with
ARVC/D and cardiac sarcoidosis showed that patients with sarcoido-
sis had reduced left ventricular ejection fraction, a significantly wider
QRS, right-sided apical VT, and more inducible forms of monomor-
phic VT.48 Furthermore, cardiovascular magnetic resonance and
specifically the cardiac volume, in addition to the degree and loca-
tion of cardiac involvement, can be used to distinguish between
these two disease entities.49 The combined use of signal and wall
motion parameters of cardiovascular magnetic resonance has been
proposed to be contemporaneously considered for achieving a better
diagnostic accuracy for the diagnosis of ARVC/D.50
4.3 | Genetic studies, biopsy, and histology
Genetic testing can identify desmosomal mutations in approximately
30%-60% of ARVC/D cases.51,52 Of these, PKP2 mutations are most
frequently observed, with an estimated prevalence of 10%-47%
among unrelated probands and 70%-82% among familiar ARVC/D
cases.10,53 The second commonest mutated gene is desmoplakin
(DSP).1 Endomyocardial biopsy guided by voltage mapping may pro-
vide ARVC/D diagnosis confirmation.54
The main macroscopical features of ARVC/D are shown in a
short-axis section of an explanted heart at the time of heart trans-
plantation for ARVC/D (Figure 7). This demonstrates a grossly
dilated right ventricle. The ventricular wall is widely replaced by fat
tissue. There are prominent right ventricular trabeculations, and the
muscular tissue of the numerous right ventricular trabecules appears
to be preserved.
In terms of histology, the hallmark of the disease is fibro-fatty
replacement of the right ventricular myocardium and right ventricular
part of the interventricular septum. Figure 8 shows full-thickness
sections of anterior right ventricular wall and interventricular septum
submitted from the explanted heart shown in Figure 7. On hema-
toxylin and eosin stain (left), there is an abrupt transition between
small areas of preserved myocardium and areas of transmural fibro-
fatty replacement in the anterior right ventricular wall and right ven-
tricular myocardium of interventricular septum. Collagen stains, such
Epsilon wave
F IGURE 4 An electrocardiogram (ECG)
showing the presence of an epsilon wave
(black arrow) that is pathognomonic of
arrhythmogenic right ventricular
cardiomyopathy/dysplasia (ARVC/D)
F IGURE 5 Modified four-chamber view during transthoracic
echocardiography demonstrating a dilated right ventricle
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as Sirius red (right), are useful to visualize areas of fibrosis in the RV
wall.
Immunohistochemistry for plakoglobin is often equivocal and
shows, as in this confirmed case of ARVC/D, a variegated staining
pattern with focal normal staining reaction in section submitted from
interventricular septum (IVS) (left), and a decreased staining reaction
in a transmural tissue section from RV, which corresponds to an
abrupt transition to an area of fibro-fatty replacement (right)
(Figure 9).
4.4 | Differential diagnosis
It is important to differentiate ARVC/D from other right ventricular
disorders, such as Brugada syndrome, as overlapping features may
be found.55 Moreover, cardiovascular conditions such as peripartum
cardiomyopathy46 or athlete’s heart can present with similar clinical
and imaging findings.56 A correct diagnosis is important because
unlike ARVC/D, athlete’s heart would not justify disqualification
from competitive sports.56 Distinguishing between ARVC/D and ath-
lete’s heart remains a diagnostic challenge. High-level endurance
training is associated with RV elongation, dilation, and hence
enlargement compared to isometric physical activities.57 As such, an
enlarged RV dimension alone is not a reliable diagnostic criterion for
ARVC/D in elite athletes. A large proportion of athletes also express
echocardiographic morphological findings often evident in docu-
mented ARVC/D, including rounded RV apex, and prominent RV tra-
beculations and moderator band.58 By contrast, impaired RV systolic
function is associated only with ARVC/D and not with athlete’s
heart. The use of both RV dilation and systolic dysfunction might
serve as a useful diagnostic tool to separate between the two.
Despite all the imaging parameters, and new normal specific ranges
for athletes,58 reaching a diagnosis of ARVC/D in an athlete can
sometimes remain challenging and a short period of detraining with
subsequent assessment usually with cardiac MRI can be helpful in
resolving this ambiguity.59
5 | MANAGEMENT
In ARVC/D, the main goal is to avoid the high-risk events of malig-
nant arrhythmias and SCD and slow the progression of heart fail-
ure.2,60 Competitive sports are discouraged.2,61 While patients with
ARVC are allowed to perform exercise including sports as part of a
healthy lifestyle, they should not exercise to maximal capacity and
be vigilant to any symptoms of palpitations.20 Frequent endurance
exercise increases the risk for VT/VF and heart failure.20The
management of patients with ARVC/D in specific situations such as
pregnancy is beyond the scope of this review, but is directed to
the following reference.62 Anti-arrhythmic medications, such as
F IGURE 6 Four-chamber view of a
cardiovascular magnetic resonance study in
diastole (left panel) and systole (right
panel) showing a very dilated RV
F IGURE 7 Short-axis section of an explanted heart at the time
of heart transplantation for ARVC/D demonstrates the right
ventricular wall to be composed of fat tissue, and there is prominent
right ventricular trabeculation. The myocardium of the numerous
prominent trabecles appears macroscopically unaffected, which has
been confirmed histologically
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beta-blockers and class-III agents, are advised.2 Sotalol and amio-
darone with or without the need for conventional beta-blockers are
potent (effective is used in 3 sentences in a row).16,63 Calcium chan-
nel blockers may be effective in selected patients.64 The addition of
flecainide in combination with sotalol/metoprolol may be an ade-
quate strategy for the control of ventricular arrhythmias in patients
with ARVC/D refractory to single-agent therapy and/or catheter
ablation.65 In general, the most sufficient combinations appear to be
sotalol or flecainide and amiodarone/beta-blockers.64
The American College of Cardiology, the American Heart Associ-
ation and the European Society and Cardiology recommended ICD
implantation for the prevention of SCD events.66 Risk stratification
and indication to ICD implantation in ARVC/D has been proposed
by an international task force consensus statement.67 One study
reported that the annual cardiac mortality in patients with ARVC/D
who were implanted with an ICD was 0.9%.68 Finally, VT ablation
targeting late potentials abolition seems to be effective in preventing
VT recurrence in patients with or without RV structural abnormali-
ties.69 In the multicenter registry, clinical response (freedom from
SCD, VT requiring hospitalization, or heart transplantation) after the
last ablation (predominantly endocardial) was 86% at 1 year, 69% at
5 years, and 60% at 10 years.70 On the other hand, the combined
endocardial and epicardial approach resulted in better procedural
success and long-term VT-free survival compared with the endocar-
dial approach in ARVC/D patients with recurrent VTs.71,72 In fact,
the combined endocardial and epicardial VT ablation eliminated all
clinical and induced VTs, and the addition of scar dechanneling
resulted in noninducibility in all cases.72 Identification of conducting
channels (CCs) inside or between the scars can be achieved via
endocardial high-density substrate mapping.73
However, another single-center study showed that the vast
majority of critical VT circuits were epicardial while epicardial abla-
tion of VT appeared to be both safe and effective in achieving
arrhythmia control in ARVC/D.74 A recent meta-analysis showed
better outcomes with the combined endocardial and epicardial abla-
tion approach compared with the endocardial approach only.75 How-
ever, a stepwise approach with an endocardial ablation first and
additional epicardial ablation only if VT episodes are still inducible
has been proposed.76,77 Furthermore, an inducibility-guided catheter
ablation strategy of VT in patients with ARVC/D has been proposed
to prevent unnecessary epicardial ablation procedures.78 Electrical
regression of SAECG after catheter ablation in ARVC/D has been
found to be associated with fewer ventricular arrhythmia recur-
rences.79 Other treatment options like bilateral cardiac sympathec-
tomy need to be studied further in order to investigate its optimal
timing and use in ARVC/D management.80
F IGURE 8 Full-thickness section of the anterior right ventricular (RV) wall and interventricular septum (IVS) including epicardial fat (EF)
using conventional hematoxylin and eosin (H&E) (left) and collagen stains (Sirius red) (right) at 90.42 magnification. There is patchy fibro-fatty
replacement of the muscular wall affecting the anterior right ventricular wall and the right interventricular septum. The myocardial architecture
of the left IVS is unaffected. Asterisk: coronary artery. The single-headed arrow points toward endocardium. The double-headed arrow marks
the areas affected by fibro-fatty replacement
F IGURE 9 Plakoglobin staining from different areas of right-sided interventricular septum, at 910 magnification. There is a variegated
staining reaction with focal positive staining, and abrupt transition to an area of fibro-fatty replacement showing negative staining reaction for
Plakoglobin in rare cardiomyocytes (encircled) (left). There is patchy mild decreased staining reaction of heart muscle cells adjacent to
hyalinized mid-wall fibrosis. The endocardium is marked by an asterisk. The double-headed arrow marks the area of subendocardial fibrous
replacement
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Individuals who present with congestive heart failure are man-
aged with diuretics and angiotensin-converting enzyme (ACE) inhibi-
tors or aldosterone inhibitors, with heart transplantation considered
in terminal stages of the disease. Anticoagulation may be used in
ARVC/D patients with large, hypokinetic RV and slow blood flow
because of the risk of thrombosis.81 Management of family members
of patients with ARVC/D is complex due to the incomplete pene-
trance and variable expressivity nature of the disease. This is beyond
the scope of this review, and the reader is referred to the article
here.44
6 | PROGNOSTICATION
There are many factors that have been associated with adverse out-
comes in patients with ARVC/D. These include clinical characteristics
such as male gender, heart rate variability, and atrial arrhyth-
mias.28,82-84 Other important factors include electrocardiographic
characteristics (atrioventricular block, T-wave inversions),83,85
echocardiographic parameters (RV diameter),86 and genetic factors
(PKP2 carriers),87 all of which are associated with higher likelihood
of ventricular arrhythmias, heart failure, and death. Biomarkers such
as soluble ST2 have been associated with RV and LV functions in
patients with ARVC/D and may aid in the determination of disease
severity in this disease.88
7 | CONCLUSION
ARVC/D is an inherited disease characterized by fibro-fatty replace-
ment of the right ventricular myocardium, which significantly
increases the risk of paroxysmal ventricular arrhythmias and SCD.
Diagnosis is based on the 2010 modified Task Force criteria, requir-
ing clinical and family history, electrocardiography, and imaging.
Diagnosis may be confirmed by endomyocardial biopsy, if the tissue
is harvested from right ventricular wall or right interventricular sep-
tum and not from prominent right ventricular trabeculae. A further
personalized approach in the management of the patients should be
undertaken by specialists in high-volume centers to enable practice
of evidence-based medicine in this condition with high morbidity
and mortality.
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